Canadian Researchers Obtain A Simple Cure For Cancer, But Major Pharmaceutical Corporations Aren’t Interested

Source

EDMONTON, CANADA, May 14, 2011 /NewsRelease/ - Canadian scientists tested dichloroacetate (DCA) on human’s cells; it killed lung, breast and brain cancer cells and left the healthy cells alone. It was tested on Rats inflicted with severe tumors; their cells shrank once they were fed with water supplemented with DCA. The drug is widely available and is easy to use, so why the major drug companies aren’t involved? Or the Media thinking about this find?

Pharmaceutical companies are not investing in this cancer research because DCA method cannot be patented

Researchers at the University of Alberta, in Edmonton, Canada have cured cancer, yet there is a little ripple in the news or in TV. It’s a simple technique using very basic drug. The method employs dichloroacetate, which is currently used to treat metabolic disorders. So, there isn’t any concern of side effects or about their long-term effects.

This drug doesn’t require a patent, so anyone can employ it widely and cheaply compared to the costly cancer drugs made by major pharmaceutical companies.

In human bodies there is a natural cancer fighting Mitochindria, the powerhouse/engine of the human cell, however they need to be triggered to work. Scientists used to think these mitochondria cells were damaged and thus ineffective against cancer. So they used to focus on glycolysis, that is less effective in curing cancer and more wasteful. The drug manufacturers focused on this glycolysis method to fight cancer. This DCA however doesn’t rely on glycolysis instead on mitochondria; it triggers the mitochondria which in turn fights the cancer cells.

The side effect of this could it be also reactivates a process called apoptosis. You see, mitochondria contain an all-too-important self-destruct button that can not be pressed in cancer cells. Without it, tumors grow larger as cells refuse to be extinguished. Fully functioning mitochondria, thanks to DCA, can once again die.

With glycolysis switched off, the body produces less lactic acid, so the bad tissue around cancer cells doesn’t break down and seed new tumors.

Pharmaceutical companies are not investing in this research because DCA method cannot be patented, without a patent they can’t make money, like they are doing with their AIDS Patent. Because the pharmaceutical companies won’t develop this, the article says other independent laboratories should start producing this drug and do more research to confirm all the above findings and produce drugs. All the groundwork can be achieved in collaboration with the Universities, who will be glad to assist in such research and may develop an effective drug for curing cancer.

You can access the original research for this cancer here.

The updated clinical trials can be found here - http://www.medicorcancer.com/dca-data.html

The latest DCA research information -http://www.dca.med.ualberta.ca/Home/Updates/2010-05-12_Update.cfm

The University of Alberta results are encouraging and support the need for larger clinical trials with DCA. The research team hopes to secure additional funding to continue the ongoing trials with DCA at the University of Alberta.

From wiki

Dichloroacetic acid, often abbreviated DCA, is the chemical compound with formula CHCl2COOH. It is an acid, an analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. The salts and esters of dichloroacetic acid are called dichloroacetates. Salts of DCA have been studied as potential drugs because they inhibit the enzyme pyruvate dehydrogenase kinase.

Cancer cells change the way they metabolize oxygen in a way that promotes their survival. In laboratory studies of isolated cancer cells grown in tissue culture, DCA restores the original metabolism, and promotes their self-destruction. This has led to the use of DCA for treating cancer, by individuals experimenting with it themselves, by doctors administering it to patients as a non-approved drug, by scientists testing it in cancer tissue cultures in cell culture and in mice, and in human Phase II studies. DCA has improved certain biochemical parameters, but it has not demonstrated improved survival.

A study in mice at the University of Alberta showed that "DCA induces apoptosis, decreases proliferation, and inhibits tumor growth, without apparent toxicity."[4] In 2010, a small human trial on 5 cancer patients and 49 samples of tissue was conducted.[5] The results were encouraging and DCA "appeared to extend the lives of four of the five study participants".[6]